Boston Scientific (NYSE:BSX) Price Target Cut to $48.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its price objective dropped by analysts at Citigroup from $50.00 to $48.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Citigroup’s price objective would indicate a potential upside of 12.93% from the company’s current price.

A number of other brokerages have also recently issued reports on BSX. BTIG Research reduced their target price on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Finally, Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $67.88.

Boston Scientific Trading Down 0.2%

BSX traded down $0.10 during trading on Monday, reaching $42.50. 9,294,325 shares of the company’s stock were exchanged, compared to its average volume of 18,722,592. The company’s fifty day moving average price is $46.95 and its 200-day moving average price is $51.51. The firm has a market capitalization of $61.60 billion, a PE ratio of 17.20, a P/E/G ratio of 1.02 and a beta of 0.58. Boston Scientific has a fifty-two week low of $41.94 and a fifty-two week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the business posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific will post 3.25 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock worth $9,385,210 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in BSX. BlackRock Inc. bought a new stake in shares of Boston Scientific in the second quarter valued at about $5,534,781,000. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after buying an additional 920,495 shares in the last quarter. Primecap Management Co. CA acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $2,156,233,000. Jupiter Topco LLC bought a new stake in Boston Scientific in the 2nd quarter valued at approximately $803,357,000. Finally, Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.